WYAMYCIN E Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Wyamycin E, and what generic alternatives are available?
Wyamycin E is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in WYAMYCIN E is erythromycin ethylsuccinate. There are one hundred and three drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the erythromycin ethylsuccinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Wyamycin E
A generic version of WYAMYCIN E was approved as erythromycin ethylsuccinate by ARBOR PHARMS LLC on December 31st, 1969.
Summary for WYAMYCIN E
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 54 |
Patent Applications: | 1,569 |
Formulation / Manufacturing: | see details |
DailyMed Link: | WYAMYCIN E at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for WYAMYCIN E
US Patents and Regulatory Information for WYAMYCIN E
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Ayerst | WYAMYCIN E | erythromycin ethylsuccinate | SUSPENSION;ORAL | 062123-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Wyeth Ayerst | WYAMYCIN E | erythromycin ethylsuccinate | SUSPENSION;ORAL | 062123-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |